Mursla Bio is a Cambridge-based liquid biopsy company, decoding cellular messengers to enable curative treatments.  Its first-in-class In Vitro Diagnostic (IVD) blood test is based on the AI-empowered analysis of the multi-omics content of liver-derived extracellular vesicles from blood, enabling a non-invasive liver biopsy at any time. Its flagship test aims to replace ultrasound for the surveillance of liver cancer among 10 million high-risk patients in Western countries.